ATE209920T1 - Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom - Google Patents

Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom

Info

Publication number
ATE209920T1
ATE209920T1 AT96931876T AT96931876T ATE209920T1 AT E209920 T1 ATE209920 T1 AT E209920T1 AT 96931876 T AT96931876 T AT 96931876T AT 96931876 T AT96931876 T AT 96931876T AT E209920 T1 ATE209920 T1 AT E209920T1
Authority
AT
Austria
Prior art keywords
antimineralcorticoid
compounds
drug withdrawal
withdrawal syndrome
warm
Prior art date
Application number
AT96931876T
Other languages
English (en)
Inventor
Francis Petit
Daniel Philibert
Nick Goeders
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE209920T1 publication Critical patent/ATE209920T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT96931876T 1995-09-21 1996-09-19 Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom ATE209920T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9511086A FR2739029B1 (fr) 1995-09-21 1995-09-21 Nouvelle application therapeutique des composes antimineralo-corticoides
PCT/FR1996/001459 WO1997010827A1 (fr) 1995-09-21 1996-09-19 Utilisation des composes antimineralocorticoides contre le syndrome de sevrage des narcotiques

Publications (1)

Publication Number Publication Date
ATE209920T1 true ATE209920T1 (de) 2001-12-15

Family

ID=9482793

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96931876T ATE209920T1 (de) 1995-09-21 1996-09-19 Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom

Country Status (10)

Country Link
US (3) US6147066A (de)
EP (1) EP0863760B1 (de)
JP (1) JP2000513704A (de)
AT (1) ATE209920T1 (de)
DE (1) DE69617729T2 (de)
DK (1) DK0863760T3 (de)
ES (1) ES2166001T3 (de)
FR (1) FR2739029B1 (de)
PT (1) PT863760E (de)
WO (1) WO1997010827A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE332696T1 (de) 1997-10-06 2006-08-15 Univ Leland Stanford Junior Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
EP1726307A3 (de) * 1997-10-06 2007-04-04 The Board Of Trustees Of The Leland Stanford Junior University Methode zur Behandlung von durch Glycocorticoidstörungen verursachten Psychosen
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
WO2003078394A1 (en) * 2002-03-15 2003-09-25 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
US8445469B2 (en) * 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
US8228301B2 (en) * 2007-07-31 2012-07-24 Kent Displays Incorporated Multiple color writing tablet
US8139039B2 (en) * 2007-07-31 2012-03-20 Kent Displays, Incorporated Selectively erasable electronic writing tablet
WO2009111574A2 (en) * 2008-03-05 2009-09-11 Evestra, Inc. BISMETHYLENE-17α CARBOLACTONES AND RELATED USES
JP5847705B2 (ja) * 2009-05-28 2016-01-27 ケント ディスプレイズ インコーポレイテッド 筆記タブレット情報記録デバイス
US9134561B2 (en) 2011-11-01 2015-09-15 Kent Displays Incorporated Writing tablet information recording device
US9235075B2 (en) 2012-05-22 2016-01-12 Kent Displays Incorporated Electronic display with patterned layer
US9116379B2 (en) 2012-05-22 2015-08-25 Kent Displays Incorporated Electronic display with semitransparent back layer
US10088701B2 (en) 2013-11-01 2018-10-02 Kent Displays Inc. Electronic writing device with dot pattern recognition system
US9851612B2 (en) 2014-04-02 2017-12-26 Kent Displays Inc. Liquid crystal display with identifiers
TWI646971B (zh) * 2015-12-04 2019-01-11 鄭恩哲 阻斷海洛因或嗎啡毒品中毒路徑的點滴處方及其應用
RU2019126483A (ru) 2017-01-23 2021-02-24 Ридженерон Фармасьютикалз, Инк. Варианты 17-бета-гидроксистероиддегидрогеназы 13 (hsd17b13) и их применение
KR20190139869A (ko) * 2017-04-11 2019-12-18 리제너론 파마슈티칼스 인코포레이티드 하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정
AU2018348195B2 (en) 2017-10-11 2025-05-15 Regeneron Pharmaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
AU2019239971B2 (en) 2018-03-21 2025-09-11 Regeneron Pharmaceuticals, Inc. 17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413993A (en) * 1991-08-20 1995-05-09 Gen-Ichiro Soma Method for the treatment of narcotic withdrawal symptoms in animals using lipopolysaccharides
US5869474A (en) * 1997-05-16 1999-02-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Low dosage treatment for cocaine craving and withdrawal

Also Published As

Publication number Publication date
EP0863760A1 (de) 1998-09-16
PT863760E (pt) 2002-05-31
JP2000513704A (ja) 2000-10-17
DE69617729T2 (de) 2002-08-08
US6759399B1 (en) 2004-07-06
ES2166001T3 (es) 2002-04-01
US20040242552A1 (en) 2004-12-02
DK0863760T3 (da) 2002-04-02
FR2739029B1 (fr) 1997-11-21
EP0863760B1 (de) 2001-12-05
FR2739029A1 (fr) 1997-03-28
WO1997010827A1 (fr) 1997-03-27
US6147066A (en) 2000-11-14
DE69617729D1 (de) 2002-01-17

Similar Documents

Publication Publication Date Title
ATE209920T1 (de) Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom
DE69738615D1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
DE69332624D1 (de) WUNDHEILMITTEL UND BEHANDLUNG VON FIBROTISCHEN STORUNGEN DURCH TGFbeta-3
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
DE69814394D1 (de) Verwendung von levobupivacain
EA199800866A1 (ru) Способ снятия боли
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
ATE208201T1 (de) Verfahren zur behandlung von neoplastischen erkrankungen unter verwendung von tiazofurin und ribavirin
DE69636907D1 (de) Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose
EA200000693A1 (ru) Антагонисты хемокинного рецептора и способы их применения
DE69733557D1 (de) Endothelin-antagonisten zur behandlung von herzversagen
ATE100826T1 (de) Behandlung von celluloseblaettern.
DE69924979D1 (de) Behandlung von chronischen schmerzen
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
NO984198D0 (no) Fremgangsmåte for behandling av aggresjon
DE69831959D1 (de) Verwendung von (E)-metanicotinederivate als Analgetika
EA199800818A1 (ru) Способ лечения бессонницы
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
RU94002713A (ru) Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда)
ITUD940153A0 (it) Iniettore per iniezioni transcutanee senza ago
UA35855A (uk) Спосіб лікування пилового бронхіту

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee